| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Don H. Linszen | Q56514651 |
| Jim van Os | Q2214357 | ||
| Robin Murray | Q7352679 | ||
| P2093 | author name string | Cécile Henquet | |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 608-612 | |
| P577 | publication date | 2005-06-23 | |
| P1433 | published in | Schizophrenia Bulletin | Q4049133 |
| P1476 | title | The environment and schizophrenia: the role of cannabis use. | |
| P478 | volume | 31 |
| Q30478069 | A classification of sociomedical health indicators: perspectives for health administrators and health planners |
| Q36364218 | A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches |
| Q37208950 | A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder |
| Q37403879 | A virtue analysis of recreational marijuana use. |
| Q35356756 | AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder |
| Q38379526 | Adolescent Initiation of Cannabis Use and Early-Onset Psychosis |
| Q37305934 | Adolescent cannabis problems and young adult depression: male-female stratified propensity score analyses. |
| Q34201476 | Adolescent exposure to cannabis as a risk factor for psychiatric disorders |
| Q34370550 | Alteration of imprinted Dlk1-Dio3 miRNA cluster expression in the entorhinal cortex induced by maternal immune activation and adolescent cannabinoid exposure |
| Q48435557 | An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition |
| Q46831405 | Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia |
| Q35216075 | Anti-social personality characteristics and psychotic symptoms: Two pathways associated with offending in schizophrenia |
| Q36982133 | Anxiety disorders and drug dependence: evidence on sequence and specificity among adults |
| Q38608656 | Applications of the Neonatal Quinpirole Model to Psychosis and Convergence upon the Dopamine D2 Receptor |
| Q22252228 | Assessing evidence for a causal link between cannabis and psychosis: A review of cohort studies |
| Q37237991 | Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis |
| Q34251969 | Blurred boundaries: the therapeutics and politics of medical marijuana |
| Q38959085 | CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex |
| Q36582466 | Cannabinoid agonists increase the interaction between β-Arrestin 2 and ERK1/2 and upregulate β-Arrestin 2 and 5-HT(2A) receptors |
| Q34899462 | Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. |
| Q34311721 | Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. |
| Q37104197 | Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D₂ receptors in rat prefrontal cortex |
| Q37075652 | Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats. |
| Q28241328 | Cannabinoids and psychosis |
| Q78878849 | Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis |
| Q48266484 | Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. |
| Q51969760 | Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. |
| Q31095554 | Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? |
| Q34830407 | Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. |
| Q24628837 | Cannabis and psychosis/schizophrenia: human studies |
| Q34398604 | Cannabis controversies: how genetics can inform the study of comorbidity |
| Q56059693 | Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis |
| Q37643444 | Cannabis use and cognition in schizophrenia |
| Q29353920 | Cannabis use and genetic predisposition for schizophrenia: a case-control study. |
| Q39751953 | Cannabis use and psychosis: re-visiting the role of childhood trauma |
| Q28238516 | Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review |
| Q50733828 | Cannabis use as an indicator of risk for mental health problems in adolescents: a population-based study at secondary schools. |
| Q41498847 | Cannabis use in male and female first episode of non-affective psychosis patients: Long-term clinical, neuropsychological and functional differences |
| Q34699888 | Cannabis, the mind and society: the hash realities |
| Q50745924 | Changes in the diagnosed incidence of early onset schizophrenia over four decades. |
| Q94562591 | Childhood trauma and substance use underlying psychosis: a systematic review |
| Q47126115 | Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment |
| Q37544803 | Chronic toxicology of cannabis |
| Q46572556 | Cigarette smoking and cannabis use are equally strongly associated with psychotic-like experiences: a cross-sectional study in 1929 young adults |
| Q88736565 | Cingulo-opercular network efficiency mediates the association between psychotic-like experiences and cognitive ability in the general population |
| Q41192138 | Cognitive neuropsychological functioning in New Zealand Māori diagnosed with schizophrenia |
| Q45171625 | Combined grey matter VBM and white matter TBSS analysis in young first episode psychosis patients with and without cannabis consumption |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q41040248 | Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis |
| Q34142822 | Consistent etiology of severe, frequent psychotic experiences and milder, less frequent manifestations: a twin study of specific psychotic experiences in adolescence. |
| Q35784024 | Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence |
| Q33372366 | Correlations between risk gene variants for schizophrenia and brain structure anomalies |
| Q36843687 | DSM-V research agenda: substance abuse/psychosis comorbidity |
| Q49351875 | Demographic and socioenvironmental predictors of premorbid marijuana use among patients with first-episode psychosis. |
| Q48043726 | Depression, marijuana use and early-onset marijuana use conferred unique effects on neural connectivity and cognition |
| Q21203727 | Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis |
| Q92541706 | Determining factors for Cannabis use among Moroccans Schizophrenic Patients: A cross sectional study |
| Q40209149 | Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. |
| Q34300051 | Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas |
| Q90263481 | Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model |
| Q94599546 | Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users? |
| Q39977976 | Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. |
| Q38076103 | Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis |
| Q48722624 | Does giving up substance use work for patients with psychosis? A systematic meta-analysis |
| Q24643912 | Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia? |
| Q34509725 | Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light |
| Q46870611 | Effect of illness expression and liability on familial associations of clinical and subclinical psychosis phenotypes |
| Q30489165 | Effect of social isolation on CB1 and D2 receptor and fatty acid amide hydrolase expression in rats |
| Q34128935 | Effects of cannabis use on age at onset in schizophrenia and bipolar disorder |
| Q33886277 | Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans |
| Q42317501 | Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction |
| Q57403291 | Environmental Risk Factors for Schizophrenia |
| Q24643547 | Environmental studies of schizophrenia through the prism of epigenetics |
| Q36919282 | Epidemiology of schizophrenia: review of findings and myths |
| Q51877145 | Estimating the prevalence of schizophrenia among New Zealand Maori: a capture-recapture approach. |
| Q43761101 | Evidence for a persistent, environment-dependent and deteriorating subtype of subclinical psychotic experiences: a 6-year longitudinal general population study. |
| Q44306383 | Evidence of increasing age of onset of cannabis use among younger Australians |
| Q35390514 | Examining a cognitive model of persecutory ideation in the daily life of people with schizophrenia: a computerized experience sampling study |
| Q34604297 | From environment to therapy in psychosis: a real-world momentary assessment approach |
| Q36890617 | G-protein receptor kinase 5 regulates the cannabinoid receptor 2-induced up-regulation of serotonin 2A receptors. |
| Q24643510 | Gene-environment interplay between cannabis and psychosis |
| Q40644644 | Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins |
| Q50508007 | Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. |
| Q30442031 | Genetics, cognition, and neurobiology of schizotypal personality: a review of the overlap with schizophrenia |
| Q26865311 | Gone to Pot - A Review of the Association between Cannabis and Psychosis |
| Q48411622 | Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol |
| Q24651025 | High-potency cannabis and the risk of psychosis |
| Q48317095 | Identification of problems in the functioning of individuals with schizophrenia from the expert perspective: an Internet-based survey |
| Q33762566 | Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations |
| Q34668606 | Impact of Cannabis Use on the Development of Psychotic Disorders |
| Q36652502 | Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC. |
| Q47950591 | Impulsivity in unaffected adolescent biological relatives of schizophrenia patients |
| Q35950814 | Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis |
| Q46370479 | Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia |
| Q36374175 | Is cannabis use psychotogenic? |
| Q58560825 | Marijuana Use in the Era of Changing Cannabis Laws: What Are the Risks? Who is Most at Risk? |
| Q38846591 | Mechanisms contributing to prefrontal cortex maturation during adolescence. |
| Q34514461 | Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. |
| Q26744408 | MicroRNA: Small RNA mediators of the brains genomic response to environmental stress |
| Q30432026 | Mouse models of gene-environment interactions in schizophrenia |
| Q38614141 | New discoveries in schizophrenia genetics reveal neurobiological pathways: A review of recent findings |
| Q34378233 | Pathways from cannabis to psychosis: a review of the evidence |
| Q35660845 | Perineuronal nets and schizophrenia: the importance of neuronal coatings |
| Q37309718 | Peripheral endocannabinoid system dysregulation in first-episode psychosis |
| Q34589479 | Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence |
| Q48139337 | Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology. |
| Q36645171 | Predictors of Self-Stigma in Schizophrenia: New Insights Using Mobile Technologies |
| Q33904544 | Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder |
| Q39876127 | Prevalence and risk factors of psychotic symptoms: in the city of Izmir, Turkey |
| Q47104449 | Prospects for Modeling Abnormal Neuronal Function in Schizophrenia Using Human Induced Pluripotent Stem Cells |
| Q45970512 | Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency |
| Q37015383 | Psychosis as a transdiagnostic and extended phenotype in the general population. |
| Q35878734 | Psychosis risk as a function of age at onset: a comparison between early- and late-onset psychosis in a general population sample |
| Q46340259 | Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes |
| Q35654533 | Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors. |
| Q33932087 | Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia |
| Q35547422 | Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats |
| Q90325053 | Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention |
| Q22242092 | Schizophrenia |
| Q36707637 | Schizophrenia in black Caribbeans living in the UK: an exploration of underlying causes of the high incidence rate |
| Q22251476 | Schizophrenia, “Just the Facts”: What we know in 2008 |
| Q37727560 | Schizophrenia--time to commit to policy change |
| Q59117302 | Schizophrenia: The Epidemiological Horizon |
| Q37346444 | Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths |
| Q92275802 | Study to determine the prevalance of substance use and factors associated with it, in first-episode of psychosis |
| Q48821406 | Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being |
| Q53093560 | Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study. |
| Q50189246 | Testing the Validity of Taxonic Schizotypy Using Genetic and Environmental Risk Variables |
| Q34279073 | The 2nd Schizophrenia International Research Society Conference, 10-14 April 2010, Florence, Italy: summaries of oral sessions |
| Q34531537 | The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability |
| Q59052397 | The Concept of Schizophrenia: From Unity to Diversity |
| Q50326139 | The Endocannabinoid System across Postnatal Development in Transmembrane Domain Neuregulin 1 Mutant Mice |
| Q36386484 | The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia |
| Q40283819 | The burden of disease attributable to cannabis use in Canada in 2012. |
| Q36968459 | The contribution of gene-environment interaction to psychopathology. |
| Q34579928 | The contribution of social factors to the development of schizophrenia: a review of recent findings |
| Q38179246 | The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research |
| Q30459929 | The environment and susceptibility to schizophrenia |
| Q35237282 | The epidemology of schizophrenia: replacing dogma with knowledge |
| Q36898681 | The pipeline and future of drug development in schizophrenia. |
| Q34604384 | The prevention of schizophrenia |
| Q37606626 | The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11. |
| Q44298682 | The psychosis continuum in the general population: findings from the São Paulo Epidemiologic Catchment Area Study |
| Q22251457 | The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: A systematic review and meta-analysis |
| Q24644325 | The role of obstetric events in schizophrenia |
| Q42940472 | The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids |
| Q24634447 | Toxoplasma gondii and other risk factors for schizophrenia: an update |
| Q39799846 | Treating prolactinoma and psychosis: medication and cognitive behavioural therapy |
| Q38639956 | Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. |
| Q48543176 | Unravelling offending in schizophrenia: factors characterising subgroups of offenders |
| Q48174298 | Variable individual sensitivity to cannabis in patients with schizophrenia |
| Q90314548 | Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat |
| Q35876018 | Visual scan paths in first-episode schizophrenia and cannabis-induced psychosis. |
| Q33664684 | Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis |
| Q38153344 | What can we learn about schizophrenia from studying the human model, drug-induced psychosis? |
| Q36637021 | What does a mouse tell us about neuregulin 1-cannabis interactions? |
| Q34900815 | What is the mechanism whereby cannabis use increases risk of psychosis? |
| Q37159625 | What we know: findings that every theory of schizophrenia should explain. |
| Q37798832 | Young Rural People at Risk for Schizophrenia: Time for Mental Health Services to Translate Research Evidence into Best Practice of Care |
| Q83367692 | [On the trivialization of cannabis and our responsibility as physicians] |
Search more.